← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	3,876	+194	+5%	$264B
2	2 Merck MRK $358B	3,439	+224	+7%	$212B
3	3 AbbVie ABBV $501B	3,328	+216	+7%	$193B
4	4 Pfizer PFE $168B	2,940	+12	+0.4%	$112B
5	5 Amgen AMGN $235B	2,717	+215	+9%	$119B
6	6 Bristol-Myers Squibb BMY $124B	2,366	-23	-1%	$79.7B
7	7 Gilead Sciences GILD $195B	1,779	+96	+6%	$85.3B
8	8 Regeneron Pharmaceuticals REGN $82B	1,273	+96	+8%	$80.8B
9	9 Novartis NVS $286B	1,272	+50	+4%	$14.3B
10	10 AstraZeneca AZN $259B	1,131	+57	+5%	$33.4B
11	11 GSK GSK $98.2B	896	+50	+6%	$10.8B
12	12 DELISTED Exact Sciences EXAS	647	+23	+4%	$11.9B
13	13 Incyte INCY $23B	557	+28	+5%	$13.7B
14	14 Jazz Pharmaceuticals JAZZ $13.9B	500	+16	+3%	$7.03B
15	15 Exelixis EXEL $15.6B	427	+28	+7%	$6.21B
16	16 Halozyme HALO $13.8B	410	+21	+5%	$4.62B
17	17 Lantheus LNTH $6.53B	401	+1	+0.3%	$4.31B
18	18 Natera NTRA $58.3B	351	+32	+10%	$7.13B
19	19 DELISTED Immunogen Inc IMGN	327	+52	+19%	$7.54B
20	20 Takeda Pharmaceutical TAK $62.1B	307	-6	-2%	$1.19B
21	21 Guardant Health GH $22.3B	295	-1	-0.3%	$2.99B
22	22 NeoGenomics NEO $2.22B	287	+4	+1%	$2.04B
23	23 BioNTech BNTX $22.7B	281	+30	+12%	$4.28B
24	24 Qiagen QGEN $9.53B	278	0	0%	$6.15B
25	25 DELISTED Blueprint Medicines BPMC	259	+39	+18%	$5.91B